Get a different perspective on the funding of Innovative Care!
DIA is establishing a new platform to support health care innovation by connecting all stakeholders that today are key to the success of BioVentures, and to continued patient access to innovation.
DIA puts BioVentures in context!
DIA is excited to convene its 1st BioVenture Day, in a unique format with participation of a very broad set of senior Health Care stakeholders.You will be able to explore whether the current BioVenture paradigm is delivering return for patients, investors, and the Health Care system.
- Are you from Pharma R&D or Business Development?
You will hear and discuss whether highly parallel but small step innovation is sustainable for both Pharma R&D and re-imbursement. Latest research on behalf of the European Parliament has investigated the links between Pharmaceutical R&D Models and Access to Affordable Medicines.
- Are you from a small or medium sized Biotech Company?
You will get deep insights into Europe’s Biotech-ecosystem and its infrastructural and funding challenges. Also get latest information about evolving funding models and true pipeline opportunities for unmet medical need from an EMA review.
- Are you an Investor or Venture Capitalist in the biopharma space?
You will hear the views of Regulators, Payers, Policy Makers, and Patients on the value of current innovation in health care.
The DIA BioVenture Day is your gateway to meaningful insights and contacts!
Join us in Glasgow on March 28th 2017 (one day prior to the 29th DIA EuroMeeting).
Holger G. Adelmann • Senior Vice President and Managing Director
David Haerry • Member
European AIDS Treatment Group, Belgium
Joep Muijrers • Chief Financial Officer
PureTech Health, United States
Dimitrios Athanasiou, MBA • Patient Advocate
WORLD DUCHENNE ORGANIZATION (WDO) , MDA HELLAS, Greece
Julia Schueler • Owner
Helga Ruebsamen-Schaeff • Chair of the Board
Inka Heikkinen, MBA, MS, MSc • Director, Global Regulatory Policy